€ 26.99 · 4.9 (752) · In Magazzino
Over the years, immune checkpoint inhibitors (CPIs) have become a powerful treatment strategy in the field of cancer immunotherapy. In the last decade, the number of FDA-approved CPIs has been increasing prominently, opening new horizons for the treatment of a wide range of tumor types. Pointedly, three immune checkpoint molecules have been under extensive research, which include cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein-1 (PD-1) and its ligand-1 (PD-L1). Despite remarkable success, not all patients respond positively to therapy, which highlights the complexity of the tumor microenvironment (TME) and immune system. This has led to the identification of molecular biomarkers to predict response and toxicity. In addition, there has been an emerging focus on developing new delivery and targeting approaches for better drug efficacy and potency. In this review, we highlight the mechanism of action of major CPIs, their clinical impact, variation in effectiveness, response prediction, updated clinical indications, current challenges and limitations, promising novel approaches, and future directions.
IJERPH, Free Full-Text
Smaller Device Under Trial May Widen Plasmapheresis Application: Hospital Practice: Vol 14, No 4
The Business Clinic
PDF) Manfred Guttmacher
Vets & veterinary practices - Canine Arthritis Management
Latoya Thomas on LinkedIn: #navymedicine #scholarships #opportunities #benefits #nursing #medical…
Animal Clinic to Host Grand Re-Opening
PDF) Clinics and Practice: A Rapidly Developing Journal
Orange County Free Clinic
Home Page: Endocrine Practice
Clinics and Practice, Free Full-Text
Tina Gaskell posted on LinkedIn
Marco Learning's Free AP® English Literature Three-Week Writing Clinic
American homoeopathist : Free Download, Borrow, and Streaming : Internet Archive
Clinics and Practice An Open Access Journal from MDPI